Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $11.00 Average PT from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have been given an average rating of “Moderate Buy” by the seven ratings firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

A number of equities research analysts have recently commented on the stock. Morgan Stanley upped their target price on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Friday, June 21st. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, July 18th. They set an “outperform” rating and a $14.00 target price on the stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $11.40 on Friday. The stock has a 50-day simple moving average of $9.50 and a 200-day simple moving average of $9.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.37 and a current ratio of 10.37. Centessa Pharmaceuticals has a 1 year low of $5.15 and a 1 year high of $12.45. The stock has a market capitalization of $1.15 billion, a PE ratio of -8.03 and a beta of 1.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. On average, analysts predict that Centessa Pharmaceuticals will post -1.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently bought and sold shares of CNTA. China Universal Asset Management Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 69.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after acquiring an additional 4,423 shares during the last quarter. Quarry LP purchased a new stake in Centessa Pharmaceuticals during the 4th quarter worth about $48,000. EntryPoint Capital LLC purchased a new position in Centessa Pharmaceuticals in the 1st quarter valued at about $109,000. American Century Companies Inc. boosted its stake in shares of Centessa Pharmaceuticals by 1.3% during the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company’s stock worth $8,444,000 after purchasing an additional 12,031 shares during the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth about $114,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.